Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Cancer Gene Ther. 2014 Dec 12;22(1):1–8. doi: 10.1038/cgt.2014.58

Figure 1.

Figure 1

AAVrh.10BevMab directed expression of bevacizumab in the mouse CNS. A. Diagram of the mouse brain illustrates regions for expression analysis and site of vector administration. R = right; L = left. B. Relative quantification of AAVrh.10-directed bevacizumab mRNA expression per μg of total RNA in each brain region and in peripheral organs (n=3). The limit of detection denoted by the dashed line. Statistical difference by two tailed t-test to R1 and R2 p<0.01 marked with asterisk (*). There was no significant difference between R1 and R2 (p>0.4) . C. Time-dependent quantification of AAVrh.10-directed bevacizumab protein expression in each brain region compared to blood (n=4). The limit of detection denoted by the dashed line. R = right; L = left. Statistical difference by two tailed t-test to (R1,R2) p<0.05 marked with asterisk (*) and p<0.01 (**). D.AAVrh.10BevMab-mediated expression of bevacizumab in neurons of the mouse striatum. Shown is immunofluorescent assessment of coronal section of the CNS 4 wk after administration of AAVrh.10BevMab. Detection of AAVrh.10BevMab-directed expression of bevacizumab was assessed with anti-human IgG antibody (anti-IgG, green), glia cells were assessed with anti-glial fibrillary acidic protein (anti-GFAP, purple) and neurons were assessed with neuronal nuclear antigen (NeuN, red). bar = 50 μm.